Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex
AssigneeThe General Hospital Corporation
InventorsDavid E. Fisher, Qing Yu Weng, Shinichiro Kato
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions and methods of treating cancer by inhibiting histone methyltransferases alone or in combination by synergistically inhibiting a histone demethylase, or a histone deacetylase (HDAC), or a bromodomain (BRD)-containing protein, or a B-Raf kinase. In particular, the cancers have deficient of SWI/SNF chromatin remodeling complexes because of mutations in one or more of the complex's subunit members.
Claims11
A method for treating melanoma in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a small molecule inhibitor of a histone methyltransferase, wherein the histone methyltransferase comprises G9a or GLP, and wherein the melanoma cells of the subject have been determined to have an alteration in the SWI/SNF ((SWItch/Sucrose Non-Fermentable) chromatin remodeling complex,
- wherein the small molecule inhibitor is selected from the group consisting of BIX-01294, UNC0638, A-366, chaetocin, UNCO224, UNC0631, UNC0642, and UNC0646.
Dependencies are inferred from the claim text.